Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
Standard
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. / Marcellin, Patrick; Heathcote, E Jenny; Buti, Maria; Gane, Ed; Man, de; Robert, A; Krastev, Zahary; Germanidis, George; Lee, Sam S; Flisiak, Robert; Kaita, Kelly; Manns, Michael; Kotzev, Iskren; Buggisch, Peter; Buggisch, Peter; Weilert, Frank; Kurdas, Oya Ovung; Shiffman, Mitchell L; Trinh, Huy; Washington, Mary Kay; Sorbel, Jeff; Anderson, Jane; Snow-Lampart, Andrea; Mondou, Elsa; Quinn, Joe; Rousseau, Franck.
In: NEW ENGL J MED, Vol. 359, No. 23, 23, 2008, p. 2442-2455.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
AU - Marcellin, Patrick
AU - Heathcote, E Jenny
AU - Buti, Maria
AU - Gane, Ed
AU - Man, de
AU - Robert, A
AU - Krastev, Zahary
AU - Germanidis, George
AU - Lee, Sam S
AU - Flisiak, Robert
AU - Kaita, Kelly
AU - Manns, Michael
AU - Kotzev, Iskren
AU - Buggisch, Peter
AU - Buggisch, Peter
AU - Weilert, Frank
AU - Kurdas, Oya Ovung
AU - Shiffman, Mitchell L
AU - Trinh, Huy
AU - Washington, Mary Kay
AU - Sorbel, Jeff
AU - Anderson, Jane
AU - Snow-Lampart, Andrea
AU - Mondou, Elsa
AU - Quinn, Joe
AU - Rousseau, Franck
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of
AB - BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of
M3 - SCORING: Zeitschriftenaufsatz
VL - 359
SP - 2442
EP - 2455
JO - NEW ENGL J MED
JF - NEW ENGL J MED
SN - 0028-4793
IS - 23
M1 - 23
ER -